1[1]a) George SM.Epigenetic cancer therapy makes headway[J].Journal of the National Caner Institute,2006,98(20):1443-1444.b) Miloslava Fojtova,Alois Piskala,Ivan Votruba,et al.Efficacy of DNA hypomethylating capacities of 5-aza-2-deoxycytldine and its alpha anomer[J].Pharmacological Research,2007,55(1):16-22.
2[2]Ghak A,Vesely J,Sorm F.Incorporaticon of 5-azacytidine into liver ribonudeic acid of leukemic mice sensitive and resisrant to 5-azacytidine[J].Biochimica et Biophysica Acta(BBA)-Nuclei Acid and Protein Synthesis,1965,108(3):516-518.Abstraet from ScilenoeDirect.
3[3]Bodo B,Fank L.DNA methyltransferase inhibitors.Old and new drugs from an epigenetic cancer therapy[J].Trends in Pharmaeological Science.2004,25(11):551-554.
5[5]Pearly SY,Martin RP,Douglas EL,et al.An Application toward Deciphering Epigenetie Signatures of Breast Cancer[J].Clinical Cancer Research.2000,6(4):1432-1438.
6[6]Daeogen(decitabine).FDA approvaes new treatment for myelodysplastie syndromes(MDS)[D] http://www.fda.gov/bbs/topics/NEWS/2006/NEW01366.html.
7[7]Long Wong,Joan Zhou,Daniel Anderson,et al.Inactivation of p16INK4a expression in malignant mesothehoma by methylation[J].Lung Cancer,2001,38(2):131-136.
8[8]Issa JP.Decitabine[J].Current Opinion in Oneology,2003,15(6):446-451.
9[9]Wijermans P,Lubbert M,Verhoef G,et al.Low-dose 5-aza-2-deoxycytidine,a DNA hypomethylating agent,for the treatment of high-risk myelodysplastic syndrome:a multicenter phase Ⅱ study in elderly patients[J].J Clin Oncol,2000,18(5):956-962.
10[10]a) Stuart AS,Ashakumary L,David P,et al.Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression[J].Expefimemal Hematology,2007,35(2):263-273.b) Yoo CB,Cheng JC,Jones P.A Zebularine:a newdrugfor epigenetic therapy[J].Biochemical Society Transactions.2004,32(6):910-912.
